Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences (Nasdaq: TYRA) reported Q2 2026 results and updates on oral dabogratinib. Initial Phase 2 SURF302 data are expected in September 2026, and BEACH301 safety sentinel results are expected end of Q1 2027. Cash, cash equivalents and marketable securities were $353.9M, runway into 2H 2028. Q2 net loss was $45.6M.
How this was made
The 30-second read
Why it matters
This release combines quarterly financials with specific upcoming clinical milestones (SURF302 in September 2026; BEACH301 safety sentinel end of Q1 2027) and a balance-sheet update (cash and runway into 2H 2028), plus an amended ATM sales agreement that increases potential dilution capacity.
Market read
Traders can frame TYRA as an event-driven name into September 2026 (SURF302 initial data) while monitoring dilution risk from the expanded ATM and burn rate reflected in higher R&D and net loss.
What to watch
R&D expense rose sharply year over year ($39.2M vs $24.3M), and the ATM amendment enabling up to an additional $250M could cap upside if investors anticipate dilution ahead of key readouts.
Background
Tyra is a clinical-stage biotech developing oral FGFR3-selective dabogratinib across multiple potentially pivotal studies (SURF302, SURF303, BEACH301).
Ticker impact
Tyra reported Q2 2026 results and said initial SURF302 Phase 2 data are expected in September 2026, with safety from 40+ patients.
Moderate upside bias into September if trial enrollment and safety remain on track; otherwise downside risk if timelines slip or safety signals emerge.
The article provides concrete timing for SURF302 initial data, plus balance-sheet runway ($353.9M) and incremental clinical progress (BEACH301 fifth dose). These are actionable for event-driven positioning, but no new efficacy datapoint is disclosed yet.
Market effects
Reinforces investor focus on FGFR3-driven oncology and oral targeted therapies, but does not introduce a sector-wide regulatory or competitive shock.
Limited, as the news is company-specific and US-listed.
Limited, as it is primarily clinical development timing and quarterly financials.
Counterpoint
The update is largely timeline and program progression, with no new efficacy results; the market may discount the cash runway if burn remains elevated.
Key entities
- companyTyra Biosciences, Inc.
Nasdaq-listed clinical-stage biotech developing oral dabogratinib; reported Q2 2026 results and updated clinical timelines.
- drug_programdabogratinib
Oral FGFR3-selective inhibitor being studied in IR NMIBC (SURF302), LG-UTUC (SURF303), and achondroplasia (BEACH301).
- clinical_trialSURF302
Phase 2 IR NMIBC study; initial results expected in September 2026, including safety from 40+ patients and efficacy from 20+ patients in aggregate.
- clinical_trialBEACH301
Phase 2 achondroplasia study; opened a fifth dose level and expects safety sentinel results end of Q1 2027.
- executiveJonathan Day
Appointed EVP, Clinical Development to lead skeletal dysplasia development strategy.
